» Articles » PMID: 39926579

Co-Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) and Human Coronavirus HKU1 (HCoV-HKU1)

Overview
Date 2025 Feb 10
PMID 39926579
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human coronavirus HKU1 (HCoV-HKU1) are two forms of human coronaviruses known to cause respiratory tract symptoms. A co-infection with both viruses is rare, particularly in the United States.

Case Description: An 85-year-old male presented to the Emergency Department with recurrent falls, diarrhoea and cough, and whose viral panel was positive for both SARS-COV-2 and HCoV-HKU1. The patient developed bacterial pneumonia and was treated with antibacterial agents and glucocorticoids. His past medical history of atrial fibrillation required careful monitoring and subsequent discontinuation of remdesivir, a medication known to cause adverse cardiovascular effects in COVID-19 patients. The length of stay was also prolonged due to delirium and deconditioning. Ultimately, the patient required an urgent ablation followed by the placement of a permanent pacemaker, and anticoagulation therapy was initiated before discharge. The patient had a favourable outcome given the rarity of this case.

Discussion: COVID-19 patients co-infected with other human coronaviruses should be monitored for disease progression and superimposed bacterial infections. Providers should be cautious with the use of remdesivir in cases of co-infection and in severely ill COVID-19 patients who have a history of atrial fibrillation.

Learning Points: This is a rare clinical case of a patient co-infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human coronavirus HKU1 (HCoV-HKU1), two forms of coronaviruses; the report presents an epidemiological anomaly and a treatment framework.The importance of close monitoring of bacterial infections in coronavirus co-infections is reinforced.The cautious use of remdesivir in patients with a history of atrial fibrillation in severe or unique COVID-19 disease is recommended.

References
1.
Esper F, Weibel C, Ferguson D, Landry M, Kahn J . Coronavirus HKU1 infection in the United States. Emerg Infect Dis. 2006; 12(5):775-9. PMC: 3374449. DOI: 10.3201/eid1205.051316. View

2.
Shimizu M, Chihara Y, Satake S, Yone A, Makio M, Kitou H . Co-infection with Legionella and SARS-CoV-2: a case report. JA Clin Rep. 2021; 7(1):62. PMC: 8372984. DOI: 10.1186/s40981-021-00467-3. View

3.
Kanwar A, Selvaraju S, Esper F . Human Coronavirus-HKU1 Infection Among Adults in Cleveland, Ohio. Open Forum Infect Dis. 2017; 4(2):ofx052. PMC: 5466428. DOI: 10.1093/ofid/ofx052. View

4.
Al Sulaiman K, Aljuhani O, Badreldin H, Korayem G, Alenazi A, Alharbi A . The clinical outcomes of COVID-19 critically ill patients co-infected with other respiratory viruses: a multicenter, cohort study. BMC Infect Dis. 2023; 23(1):75. PMC: 9901824. DOI: 10.1186/s12879-023-08010-8. View

5.
Garcia-Vidal C, Sanjuan G, Moreno-Garcia E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M . Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2020; 27(1):83-88. PMC: 7836762. DOI: 10.1016/j.cmi.2020.07.041. View